

MEDICINES CO /DE
Form DEFA14A
May 20, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant X

Filed by a Party other than the Registrant O

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

The Medicines Company

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

Edgar Filing: MEDICINES CO /DE - Form DEFA14A

This filing relates to the 2013 annual meeting of stockholders of The Medicines Company. (the Company) and supplements the related proxy statement filed by the Company with the Securities and Exchange Commission (the SEC) on April 29, 2013 (the Proxy Statement).

The Company is providing the following supplemental, unaudited information concerning its stock incentive plans as of March 31, 2013:

Total shares underlying options outstanding under the Company s stock incentive plans at March 31, 2013 (excluding the Company s 2000 and 2010 employee stock purchase plans): 8,617,383

Weighted average exercise price per share of outstanding options: \$20.80

Weighted average remaining contractual term of outstanding options: 6.23 years

Total outstanding shares of restricted stock awards granted under the Company s stock incentive plans as of March 31, 2013: 638,455

Total shares available for future grant under the Company s stock incentive plans at March 31, 2013 (excluding the Company s 2010 employee stock purchase plan): 775,628

Company stockholders are urged to read the Proxy Statement and other relevant materials because they contain important information about the Company and proposals to be voted on at the 2013 annual meeting of stockholders. Investors may obtain a free copy of these materials and other documents filed by the Company with the SEC at the SEC s website at www.sec.gov, or by sending a written request to the Company at The Medicines Company, 8 Sylvan Way, Parsippany, New Jersey 07054, Attention: Secretary.